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ABSTRACT 
PROPENSITY SCORE MATCHING FOR SURGICAL OUTCOMES WITH 
OBSERVATIONAL DATA 
Robert M. Cannon, 3/26/2012 
Because of limitations in randomized controlled trials, medical researchers are 
often forced to rely upon studies of observational data. Confounding is a major difficulty 
encountered in such studies that can create considerable bias in estimates of treatment 
effects. Propensity score analysis was developed by Rosenbaum & Rubin in 1983 to 
overcome these difficulties. In essence, a propensity score allows balance to be 
achieved on confounding covariates in treatment and control groups, thus creating a 
'quasi-randomized' trial from observational data. In this study, I illustrate the use of 
propensity matching to demonstrate that African American race is a significant risk factor 
for receiving a lower quality donor kidney using a national database on transplantation. I 
then use propensity matching to demonstrate the benefits of laparoscopic resection for 
hepatic colorectal metastases. In doing so, the great value of propensity matching in 
reducing bias in observational studies is demonstrated. 
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CHAPTER I 
INTRODUCTION TO PROPENSITY SCORE METHODS 
The goal of much of medical research is to evaluate the effect of a 
particular intervention or exposure (which, hereafter I will refer to as a treatment) on a 
given outcome of interest. For example one may wish to determine whether a new 
chemotherapy regimen has a superior response rate compared to the current standard. 
In the hierarchy of medical evidence, the randomized controlled trial (RCT) is considered 
by many to be the gold standard for the assessment of such questions. 
There are a number of important reasons for the value given to the RCT in 
studies of causal inference. By the nature of randomization, the potential of bias in the 
allocation of patients to either the treatment or control group is eliminated. As a corollary 
to this property, a properly executed randomization scheme tends to produce treatment 
and control groups that are balanced (that is, they have similar distributions) on relevant 
covariates, both those that are measured and those that are unmeasured1. As I will 
demonstrate, these characteristics allow for unbiased estimation of the effect of the 
particular treatment under study. 
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Despite these considerable advantages, randomized controlled trials are subject 
to a number of limitations. In the first place, the costs associated with designing and 
carrying out an RCT can be expensive, particularly when a large number of subjects is 
required to achieve the desired power. Randomized controlled trials frequently contain 
stringent inclusion and exclusion criteria speciying whom is allowed to participate. Thus, 
the trial population may differ from the general population to a degree that the findings of 
the trial may not be broadly applicable, which is to stay that the study lacks external 
validitl. Finally, there are a number of circumstances where a randomized trial may be 
impractical, unethical, or even impossible. For example, if a researcher is interested in 
studying the effect of race on survival after diagnosis of a particular cancer, it would 
obviously be impossible to randomize the race of the subjects. If one wanted to study the 
effect of smoking on mortality, it would clearly be unethical to randomize subjects to 
smoking or non-smoking. 
Because of the limitations of RCTs, researchers are often forced to rely upon 
studies that are observational in nature. In an observational study, the researcher has no 
control over the treatment assignment for the subjects, instead they are "self-selected" 
into the treatment and control groups2. Subjects in the treatment and control groups thus 
may differ widely in terms of baseline covariates. A covariate that is correlated with both 
the treatment and the outcome is known as a confounder. If subjects in the treatment 
and control groups differ significantly on confounding variables, then subsequent 
estimates of the treatment effect may be subject to considerable bias if steps are not 
taken to control for the confounding factors. 
Rubin gives an example of the effect confounding can have on estimates of 
treatment effect, which I will summarize here3. Consider the case of a researcher 
wishing to study the effects of smoking on mortality. He analyzes a cohort that consists 
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of frequent smokers and nonsmokers. Consider now that the non-smokers are, on 
average, older than the smokers. If the researcher were to simply compare the mortality 
rates of the smokers to those of the nonsmokers, he may very well find that the mortality 
rate is higher in the nonsmokers. This observation does not account for the confounding 
effect of age, in that older subjects are likely to have higher mortality rates regardless of 
smoking status. If the researcher were to then re-analyze the data in a manner that 
adjusts for the age difference between groups, he would then correctly observe that 
smoking is indeed a risk factor for increased mortality. 
If the number of confounding variables were relatively few, as in the example 
above, it would be fairly straightforward to control for their effect and thus reduce the 
bias observed in estimation of the treatment effect. One of the most common methods is 
stratification, also referred to as subclassification by Cochran4 . In brief, stratification 
involves dividing the treatment and control groups into categories, or strata, based on 
the levels of the confounding variable. In the example given by Rubin above, one may 
divide the smokers and nonsmokers into categories based on age, such as younger, 
middle-aged, and 0lder3. The outcome variable can then be assessed within each strata, 
and the results combined to get the overall estimated treatment effect. By performing 
comparisons using 5 to 6 strata, Cochran has demonstrated that 90% or more of the 
bias present in unadjusted analysis may be removed4 . 
Frequently, however, there are many potential confounders for which 
investigators need to control. As the number of covariates increases, Cochran has 
demonstrated that the number of strata grows in an exponential fasion. 5 For example, a 
study with k dichotomous covariates would have 2k strata. Propensity score methods, 
initially developed by Rosenbaum and Rubin6 in 1983, provide a convenient means for 
addressing the problem of confounding by multiple covariates in observational studies 
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and have become increasingly popular over the past two decades in the medical 
literature. 
Before specifying the derivation and use of the propensity score, it will first be 
helpful to consider the conceptual framework upon which it operates, which is known as 
the potential outcomes framework, or Rubin Causal Model?' 8. In this model, there are 
two treatments (labeled 0 and 1) and an outcome of interest. For a sample of N subjects, 
the ith subject has two potential outcomes, which are Y;(O) and Y;(1), which are the 
outcomes when the ith subject receives treatment 0 and when the ith subject receives 
treatment 1, respectively. In reality, each subject only receives one treatment, either the 
active or the control. 
Now let Z be an indicator variable for the treatment assignment, where Z=O for 
the control treatment and Z=1 for the active treatment. The outcome observed for each 
subject under the treatment received thus becomes: 
The average treatment effect (ATE) thus becomes the difference between the 
expectations between Yj(1) and Yj(O), that is to say: 
ATE = ~(1) - ~(O) 
The average treatment effect is thus the effect of moving the entire population from the 
untreated to the treated condition? In other words, the ATE is an estimate of the 
difference in outcome if those who received one treatment instead received the other. In 
the RCT setting, randomization allows for direct comparison of the treatment and control 
groups. This can't be done in observational studies, however, because the subjects in 
one treatment group differ systematically from those in the other treatment group. In 
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order for direct comparisons to be meaningful in such a setting, a balancing score is 
needed to even out the differences in covariates between the two treatment groupS6. 
A balancing score, b(x) (of which the propensity score is a single example), is a 
function of the observed covariates x such that the conditional distribution of x given b(x) 
is the same for both the treated (z=1) and control (z=O) groups. That is to say, x and z 
are independent conditional on b(x). There are many balancing scores, the finest of 
which is the vector of covariates itself, x6. 
Having defined a balancing score, now we consider the distribution of the 
treatment assignments, which is as follows: 
e(x) = pr(z = llx) 
and it is also assumed that 
n 
pr(zl, ... ,ZnIXl, ... ,xn ) = n e (xaZi{l- e(xaJ1-Zi 
i=l 
In the above equation, n is the number of subjects, while Zi is the indicator for treatment 
assignment of patient i, and Xi is the vector of covariates for the ith subject. 
The probability e(x) is known as the propensity score, and represents the 
conditional probability of assignment to the treatment group, given the observed 
covariates. If two subjects have the same propensity score, then the probability that 
either of them would be assigned to the treatment group, conditional on the observed 
covariates, is also equal. Thus it is as if a coin flip was performed to determine to which 
treatment group the subject would actually be assigned. Herein lies the primary utility of 
propensity score methods, in that they create what has been termed a "quasi-
randomized" experiment from observational data9. 
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An important assumption of the propensity score is that of strongly ignorable 
treatment assignment6 , which states that treatment assignment and outcome are 
conditionally independent given the vector of covariates, and that for each subject, there 
is a possibility of assignment to either treatment group. In mathematical notation: 
~(O), Yi(l) 1- zlx, and 0 < pr(z = llx) < 1 
The first condition of strongly ignorable treatment assignment is also known as the "no 
unmeasured confounders assumption,,7. Stated yet another way, the assumption is that 
all variables that affect treatment assignment have been included in the propensity 
score. The second condition of strongly ignorable treatment assignment 
(0 < pr(z= 1 Ix) < 1), may be stated alternatively that there must be sufficient overlap in 
estimated propensity score between the treated and control groups. The region of 
overlap is known as the zone of common supporf. At a given value of the propensity 
score, the difference between the treatment and control means is an unbiased estimate 
of the average treatment effect when treatment assignment is strongly ignorable. 
In a randomized controlled trial, the propensity score is known, as the 
assignment into treatment groups is controlled by the investigators. Remember that the 
propensity score is simply the probability that a particular subject will be assigned to a 
treatment group. In an RCT, treatment assignment is solely a function of the 
randomization scheme, and thus propensity is known and subject to control by the 
investigators. In most cases, the propensity score for each subject in an RCT would thus 
be 0.5. In observational studies, on the other hand, the propensity score is unknown and 
must be estimated using the measured covariates. Although several methods for 
estimating the propensity score have been suggested10-12 , by far the most commonly 
used method is that of logistic regression6 , 7, 
6 
follows: 
In the logistic regression framework, the propensity score (p) is estimated as 
P log-l- = {J' x 
-p 
where {J' is the vector of regression coefficients and x is the vector of measured 
covariates, The major question in deriving the estimated propensity score then becomes 
which covariates to include in the logistic regression model. Possible sets of covariates 
include all measured baseline variables, all baseline covariates that affect the treatment 
assignment, all covariates that affect the outcomes (potential confounders), and all 
covariates that affect both the treatment assignment and the outcome (true 
confounders( Although there is no universal agreement on which set is the best to 
choose, there have been some studies to suggest that inclusion of only the potential or 
true confounders leads to more precise estimation of the treatment effect13, 14, Which 
variables meet these requirements will often require subject matter expertise and/or 
reference to the available literature, Austin has noted, however, that most baseline 
characteristics are likely to affect both treatment assignment and outcome, so inclusion 
of all measured baseline characteristics is generally safe?, There has been discussion in 
the literature of using goodness of fit estimates such as the c-statistic to determine the 
correct specification of the propensity score model, however such methods have been 
shown to be ineffective in reducing confounding, and may actually result in a decreased 
zone of common support between the treated and control groups 15, Thus, selection of 
covariates to include in the propensity score model should be guided as stated above by 
expert knowledge, reference to the literature, and empirical observation 15,16, 
After the propensity score has been estimated, there are three common methods 
for its use: matching on the propensity score, stratification on the propensity score, and 
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regression on the outcome of interest with the propensity score included as a covariate2, 
6,7,9. In general, matching has been demonstrated to result in greater balance between 
the treated and untreated groups than the techniques of stratification and regression?' 13, 
1? As matching (generally in a 1:1 fashion) is the most commonly employed method, and 
is the method I will feature in the following chapters, the discussion here will be limited to 
matching methodologies. 
Having decided to match on propensity scores, the investigator is faced with a 
number of choices as to how matching should actually be performed. The first choice is 
whether to match with or without replacement2'? A potential drawback of matching with 
replacement is that a single untreated subject may be matched with multiple treated 
subjects. Another decision is whether to match using a simple nearest neighbor 
algorithm (in which treated subjects are matched to untreated control with the closest 
propensity score), or whether to impose a caliper on the maximum difference in 
propensity score between the treated subject and untreated control for the match to be 
considered valid. 
If the zone of common support is limited, then simple nearest neighbor matching 
will tend to result in poor matches being made for the treated subjects at the higher end 
of the estimated propensity score distribution. In order to prevent this problem, 
imposition of a caliper that specifies the maximum difference in propensity scores has 
been proposed?' 18-20. There is no generally accepted caliper width, so the ultimate 
judgment must be based on the degree of balance achieved between the matched 
samples, as will be discussed later. Having specified an appropriate caliper, the 
investigator must then choose between "greedy" matching and "optimal" matching. 
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In a greedy matching scheme, once matches are made they are not broken? 
Thus, once a control is matched to a treated subject, that control is removed from the 
pool of potential controls for others in the treated group. An optimal matching strategy, 
on the other hand, is formulated so that matches are made which minimize the total 
distance in propensity scores between pairs. Comparison between the two schemes 
have demonstrated that optimal matching performs no better than greedy matching in 
producing balanced samples, which is the ultimate goal of propensity matching21 . Luo 
and colleagues present a nice graphical depiction of the choices facing the investigator 
when implementing propensity score techniques2. 
As stated above, the ultimate goal of propensity score matching is to create a 
cohort of treated and control subjects that are balanced on relevant covariates. Checks 
of the balance between the matched samples then becomes important to determine 
whether the estimated propensity score and matching methodology have been 
appropriately specified. In this area, there has been some controversy as to whether 
significance testing is an appropriate method for determining balance on covariates in a 
propensity matched sample. 
On the one hand, Austin and others have argued against the appropriateness of 
significance testing on the grounds that significance testing is confounded by sample 
size?' 20, 22. In Austin's view, significance tests of balance may lack power to detect 
important differences between covariates if the matched sample is small, while trivial 
differences may be declared significant if the matched sample size is large?' 20. As an 
alternative, Austin has suggested the standardized difference for continuous variables as 
a more appropriate measure of balance. The formulation for the standardized difference 
(d) is as fOllows20 : 
9 
100 * Imeantreatment - meancontroll 
d = ----;:======~=-­
SEreatment + S~ontrol 
2 
Thus we see that the standardized difference places the difference in means between 
the treatment and control in terms of the pooled variance of the two groups. There is no 
widely agreed upon cutoff to define an acceptable standardized difference, though 
Normand has defined a difference of less than 0.1 in absolute value to represent 
appropriate balance has been achieved23 
On the other hand, Hansen has argued in favor of significance testing for the 
assessment of covariate balance24 . In Hansen's view, hypothesis tests for balance tend 
to reject the null hypothesis of balance when the difference in covariates is enough to 
introduce significant bias into the subsequent causal inferences. On the other hand, 
significance tests of balance fail to reject the null hypothesis when differences between 
covariates are small enough that any subsequent bias in the causal estimates is 
ignorable. The use of significance testing for balance does have a tradition in the 
literature2, 9, 25. Luo and colleagues make the reasonable suggestion that, if hypothesis 
testing is to be used, then tests appropriate for matched pairs such as the paired t-test or 
Mcnemar's test should be chosen2. 
Having estimated propensity scores, formed matched cohorts, and appropriately 
assessed balance between the groups, the investigator is left with the final choice of how 
to perform significance testing on outcomes. The basic distinction to be made is whether 
the matched samples should be treated as independent. Schafer has argued that the 
treated and control groups in the matched sample should be regarded as independenf' 
16, which would lead to tests such as the two sample t-test for continuous outcomes and 
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Pearson's chi-squared test for categorical outcomes. Austin, on the other hand, has 
made the argument that subjects matched on important baseline covariates are liKely to 
have similar outcomes, and thus methods that account for the lack of independence 
between groups are more appropriate. In this manner, Austin suggests methods such as 
the paired t-test and Mcnemar's test for assessment of continuous and categorical 
outcomes, respectivel/. 
Having now described the basis of the propensity score and suggestions for its 
use in observational studies, I will now turn to specific examples of how the propensity 
score can be used in settings where randomized trials are either impossible or 
impractical. In the first case, the disparity in donor organ quality between African 
American and Caucasian recipients will be examined. This is a case where 
randomization is clearly impossible, as recipient race is an intrinsic characteristic of the 
patient not subject to investigator control. In the next case, outcomes after laparoscopic 
versus open resection of hepatic colorectal metastases will be evaluated. A randomized 
controlled trial in this setting is theoretically possible, but rendered infeasible given that 
patients are unlikely to agree to be randomized to a more invasive procedure26 . 
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CHAPTER II 
THE IMPACT OF DONOR QUALITY ON THE OBSERVED DISPARITY IN GRAFT 
SURVIVAL BETWEEN AFRICAN AMERICAN AND CAUCASIAN KIDNEY 
TRANSPLANT RECIPIENTS 
Kidney transplantation remains the gold standard for treatment of patients with 
end stage renal disease when compared to long term maintenance dialysis, which has 
been demonstrated across ethnic groups27. As the field of transplantation has matured a 
number of disparities in access28-30 to transplantation, as well as in post-transplant 
outcomes30-34 between African American and Caucasian recipients have come to light. 
Several authors have proposed factors contributing to these disparities, including 
socioeconomic31 , 34, 35, genetic36, immunologic37,38, and even pharmacokinetic39 issues. 
Issues of donor quality also playa major role in post-transplant outcomes. 
Kidneys from African American donors, for example, have been shown to be associated 
with an increased risk of graft loss32, 40, 41, especially when transplanted into other African 
Americans42. The importance of donor quality in post-transplant outcomes is especially 
clear when looking at kidneys from expanded criteria donors, which pose a 70% greater 
risk of graft failure than lower risk organs43 . Despite the known importance of donor 
quality, there is a relative paucity of large scale studies examining racial disparities in 
terms of donor quality in a systematic manner 44. 
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We undertook this present study to determine the presence of and any possible 
contributing factors to differences in donor quality between African American and 
Caucasian first time recipients of deceased donor kidney transplants, as well as to 
ascertain the effect of any donor quality disparity on post-transplant outcomes. 
Patients and Methods 
Selection of Patients for Analysis 
After receiving an institutional review board exemption, an analysis of the United 
Network for Organ Sharing/Organ Procurement and Transplantation Network database 
as of 3/31/2011 was performed. The target population for this study was Caucasian or 
African American first time recipients of deceased donor kidney alone transplants from 
1/1/2000 through 12/31/2009. 
Assessment of Donor Quality 
The primary goal of this study was to determine disparity in donor quality 
between African American and Caucasian recipients. The kidney donor risk index (DRI) 
derived by Rao, et al. 45 was chosen as the measure for donor quality for this study as it 
avoids the creation of arbitrary cutpoints in continuous data, and that it provides more 
granular information than more traditional measures such as the expanded donor 
criteria. The DRI includes donor age, race, history of hypertension and diabetes, serum 
creatinine, cause of death, height and weight, donation after cardiac death status, 
hepatitis C status, B and DR locus mismatch level, cold ischemic time, and whether an 
en bloc or double kidney transplant is to be performed. The score represents the 
estimated risk of graft failure relative to a hypothetical standard donor with a DRI of 1.0. 




Comparisons were made between the African American and Caucasian recipient 
cohorts. Continuous variables were summarized as mean/standard deviation and 
analyzed using Student's t-test while categorical variables were summarized as 
count/percentage and analyzed using the chi-squared or Fisher's exact test, where 
appropriate. Graft survival was calculated as the time from transplant to graft failure, with 
censoring at the time of death with a functioning graft or last follow-up (right-censoring) 
in the case of Cox proportional hazards analysis46 . The cumulative incidence of graft 
failure in African Americans versus Caucasians was calculated by competing risks 
analysis47 and compared using a modified chi-squared statistic as described by Gral8. 
In this analysis, death and graft failure were treated as competing risks, while patients 
still alive at the end of follow-up with a functioning graft were censored. 
To control for confounders related to recipient race that may influence observed 
differences in DRI, a 1: 1 propensity matched49 cohort of African American and 
Caucasian recipients was created using a nearest neighbor algorithm50. Propensity 
scores were estimated through logistic regression, with immunologic (HLA-A, -B, and-
DR antigens, peak PRA, and ABO antigen), socioeconomic (payment source, 
educational achievement, employment status, and UNOS Region), and medical (age, 
recipient bmi, etiology of renal failure, recipient diabetes status, weight, gender, recipient 
HCV status, recipient CMV status, and days on the waiting list) factors as independent 
variables and recipient race as the dependent variable. The result of this model is to 
assign each patient a propensity score that describes the probability of the patient either 
being African American or Caucasian based upon the independent variables entered in 
the model. The form of the model is as described above in Chapter I: 
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e(x) _ -1 
log 1 _ e(x) - fJ x 
Where e(x) is the propensity toward being African American, and x is the vector of 
medical, immunologic, and socioeconomic baseline covariates described above. These 
covariates were chosen on the empirical assumption that they are correlated with 
recipient race and/or donor selection (which is the desired outcome to ultimately 
analyze). Matching was on a 1: 1 nearest neighbor fashion based on the estimated 
propensity score, with a caliper of 0.1 imposed to ensure that matching was within the 
zone of common support. Furthermore, the matching algorithm was "greedy" in that once 
made, matches were not broken. African American recipients without a corresponding 
Caucasian control who had a propensity score within the specified caliper were 
discarded. 
After creation of the propensity matched cohort, balance on the covariates 
included in the model estimating the propensity score was assessed using matched pair 
techniques. Specifically, continuous covariates were compared using the paired t-test 
and the Spearman signed rank test, where appropriate. Categorical covariates were 
compared using McNemar's test or its extension for larger dimension square tables, or 
conditional logistic regression for non-square tables. Differences in the overall DRI as 
well as individual components were then assessed in the propensity matched cohort, 
again using paired data techniques as described for assessment of balance. 
To explore the contribution of DRI to disparities in graft survival between African 
Americans and Caucasians, several Cox regression models were examined in 
sequence. First univariable models were fitted with recipient race and DRI respectively 
as the sole predictor variables to determine the baseline unadjusted hazard for graft 
failure posed by these factors. Next, to control for other potentially relevant covariates, a 
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multivariable Cox regression model was fitted using forward selection of variables 
significant at the p<0.05Ievel. Factors considered in the model were the same 
covariates used to create the propensity score described above. Donor risk index was 
then included as a covariate in the third and final multivariable model. The difference 
between the hazard ratios corresponding to African Americans was then examined in the 
progressively adjusted models. Reductions in the hazard ratio would indicate that the 
additional covariates partially explain the observed disparity in graft survival between 
African American and Caucasian recipients. 
As a final test of the contribution of DRI disparity to the difference in graft survival 
between African Americans and Caucasians, graft survival was analyzed in a cohort of 
African Americans and Caucasians matched on DRI. The matching process was similar 
to that used in the propensity matching scheme, namely 1: 1 matching based on a 
nearest neighbor algorithm. The hazard ratio for African American race in this matched 
cohort was then compared to the unadjusted hazard ratio for African American race in 
the overall cohort. The percent of excess hazard explained by matching on DRI was 
calculated as (HRunmatched-HRmatched)/(HRunmatched-1 )*1 00%.51 The interaction between DRI 
and recipient race was also examined by performing Cox proportional hazards 
regression of graft survival stratified by DRI in the overall cohort. The three strata 
analyzed were DRI <1, 1 s;DRI<1.5, and DRI ~1.5. 
Sensitivity analysis was also performed to determine whether significant bias 
may have been introduced into the analysis by exclusion of patients with missing data 
that did not allow for calculation of the DRI. First, chi squared analysis was performed to 
determine whether patients with missing DRI data differed significantly by race. DRI for 
the patients with missing component variables was then calculated using multiple 
imputation, whereby five imputations were performed in which missing DRI component 
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variables were predicted based on remaining DRI variables that were available for each 
patients. The five imputations were then combined to give estimates of the mean and 
standard deviation for the DRI in subset of patients with missing data. The imputed ORis 
were then compared to the DRI for African Americans and Caucasians with complete 
data to determine whether the patients with missing data were significantly different from 
the subset with complete data. Cox proportional hazards analysis was then performed to 
determine whether graft failure in the patients with missing DRI data was significantly 
different from the patients who had complete data. All statistical analyses were 
performed using SAS version 9.3 (SAS Institute, Cary, NC), with the exception of 
competing risks analysis, which was performed in R (The R Project for Statistical 
Computing). 
Results 
Overall Recipient and Donor Characteristics 
There were 55,982 recipients included in the study with complete DRI data 
collection, of whom 33,405 (59.67%) were Caucasian and 22,577(40.33%) were African 
American. There were 3,916 Caucasians and 2,534 African Americans in the original 
dataset that had missing data for DRI and thus were not included in the analysis. The 
majority of patients analyzed were male (61.02%) at a mean age of 50.74 years at the 
time of transplant. Mean time on the waiting list was 734.02 days. Peak PRA was a 
mean of 12.79%. Remaining descriptive statistics of the recipients in this study are 
detailed in Table 2.1. 
The average age of donors was 38.14 years, with 59.70% being males 
(n=33,423) and 7,496 (13.39%) African Americans. Terminal creatinine was a mean of 
1.11 mg/dl. Cause of death was cerebrovascular accident in 21,717 (38.79%). Donation 
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after cardiac death was uncommon (8.19% of all donors) as was utilization of HCV 
positive donors (2.91%). Mean cold ischemic time was 18.59 hours. The mean DRI was 
1.21. Remaining donor characteristics are summarized in Table 2.2. 
Differences in Donor Risk Index By Recipient Race 
African American recipients received kidneys from higher risk donors as 
measured by most components of the donor risk index(table 2.1, 2.2). Specifically, 
African Americans were more likely to receive a kidney from an African American donor 
(20.37% vs. 8.67%; p<0.001). Utilization of hepatitis C positive donors was also 
significantly higher among African American compared to Caucasian recipients (5.43% 
vs. 1.20%; p<0.001). There was also a statistically significant, though likely not clinically 
significant, increase in cold ischemic time for African American recipients (18.86 vs. 
18.41 hours; p<0.001). Overall, donor risk index for African American Recipients was 
significantly higher than for Caucasian recipients (1.27 vs. 1.17; p<0.001). The 
distribution of the DRI in African American and Caucasian recipients is presented in 
figure 2.1. There was no Significant difference in the percentage of African Americans 
and Caucasians who received organs from extended criteria donors (17.66%, n=3986 
vs. 17.98%, n=6005; p=0.330). 
Propensity Matched Analysis 
Matching on propensity score yielded a cohort of 2446 Caucasian and 2446 
African American Recipients (distribution of propensity scores pre and post matching are 
presented in Figure 2.2 and Figure 2.3, respectively). The African American and 
Caucasian groups were well matched on etiology of renal failure (p=1.0), ABO type 
(p=1.0), UNOS region (p=0.95), A 1 (p=0.99), A2 (p=0.92), B1 (p=0.76), B2 (p=1.0), 
DR1 (p=0.81), and DR2 (p=0.99) haplotypes, payment source (p=1.0), HCV positivity 
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(6.17% vs. 6.13%; p=0.95), cytomegalovirus positivity(7.15% vs. 7.85%; p=0.94), gender 
(62.2% male vs. 63.0% male; p=0.55), educational achievement (p=0.91), diabetes 
status (p=0.81), age (mean difference -0.61 years, 95% CI -1.32 -0.11; p=0.10), peak 
PRA (mean difference - 0.20,95% CI -1.74 - 1.33; p=0.979), weight (mean difference-
0.58kg, 95% CI -1.69 - 0.52; p=0.30), body mass index (mean difference -0.32,95% CI -
0.78 - 0.14; p=0.17), pretransplant creatinine (mean difference -0.08mg/dl, 95% CI -0.27 
- 0.10; p=0.38), and days on the waiting list (mean difference -11.5 days, 95% CI -47.5-
24.5; p=0.53). 
In the propensity matched cohort, there remained a minor difference in mean DRI 
between the African American (1.28) and Caucasian (1.25) cohorts (mean difference 
0.03, 95% CI .005-0.06; p=0.02)(Figure 2.4). Comparison of donor risk index 
components between the two groups are outlined in table 2.3. Notably, African 
Americans are still significantly more likely than Caucasians to receive a kidney from an 
African American donor (15.74% vs. 13.41%, OR 1.21,95% CI 1.03 - 1.41; p=0.02). 
Furthermore, utilization of HCV positive donors remained significantly higher in African 
American recipients (3.97% vs. 1.96%, OR 2.06, 95% CI 1.45-2.93; p<0.001). 
Effect of Recipient Race and Donor Risk Index on Graft Survival 
Both DRI and recipient ethnicity significantly correlated with graft survival in the 
univariable models. The hazard ratio for each one point increase in DRI in the over the 
baseline of 1.0 in the unadjusted model was 2.2 (95% CI 2.071-2.239; p<0.001). One, 
five, and ten year cumulative incidence of graft failure for African Americans was 7.5% 
(95% CI 7.2%-7.9%), 25.2% (95% CI 24.5%-25.9%), and 43.9% (95% CI42.4%-45.3%) 
compared to 5.6% (95% CI 5.3%-5.8%), 14.8% (95% CI14.4%-15.3%), and 25.7% 
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(95% CI 24.8%-26.6%) (p<0.001) for the Caucasian cohort. The hazard ratio for African 
Americans relative to Caucasians in the unadjusted model was 1.8 (95% CI 1.7-1.9; 
p<0.001). The median followup for the overall, African American, and Caucasian cohorts 
was 37.2 months, 35.9 months, and 41.5 months, respectively. The number of graft 
failures (not including death with a functioning graft) in the overall, African American, and 
Caucasian cohorts were 10,132, 5,245, and 4,887, respectively. 
The multivariable Cox regression model for graft survival after forward selection 
included recipient race, age, and weight, etiology of renal failure, employment status, 
UNOS region, payment source, and recipient hepatitis C status. The hazard ratio for 
African Americans relative to Caucasians in this model was reduced to 1.5 (95% CI 1.3-
1.6; p<0.001). After entering DRI as a covariate in the above multivariable model, the 
hazard ratio for African Americans was further reduced to 1.3 (95% CI 1.2-1.4; p<0.001). 
Hazard ratios for all other covariates included in the model are presented with the 
supplementary material (Table 2.4). 
As a further test of the importance of DRI disparities on the differential graft 
survival seen with African American and Caucasian recipients, matching for donor risk 
index yielded a cohort of 22,466 African Americans and 22,466 Caucasians with a mean 
DRI of 1.26 for each group (p=1.0). The hazard ratio for African Americans relative to 
Caucasians in this matched cohort was reduced to 1.6 (95% CI1.5-1.7; p<0.001), giving 
a percent of excess hazard explained of 25%. 
Finally, examination of the interaction between DRI and race in terms of graft 
survival was undertaken using stratified analysis as outlined above. In the lowest DRI 
stratum (DRI <1.0), the HR associated with African American Race was 2.1 (95% CI 1.9-
2.2; p<0.001). In the middle stratum (1.0SDRI<1.5), the HR associated with African 
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American race decreased to 1.6 (95% CI1.5-1.7; p<0.001). In the highest DRI stratum 
(DRI~1.5), the HR associated with African American race was further reduced to 1.4 
(95% CI 1.3-1.5; p<0.001). 
Sensitivity Analysis for Missing DRI Data 
There were 2534 (10.09%) African Americans with missing DRI data compared 
to 3916 (10.49%) Caucasians (p=0.106), indicating that patients with missing DRI were 
equally distributed by race. Using multiple imputation as described above, the mean DRI 
for African Americans with missing data was predicted to be 1.26 (0.465) compared to 
1.27 (0.445) for those with complete data (p=0.486). The mean imputed DRI for 
Caucasians with missing data was 1.15 (0.482) compared to 1.17 (0.542) for those with 
complete data (p=0.058). Thus, the patients with missing data did not differ significantly 
in terms of DRI from those with complete data. In terms of graft failure, Caucasians with 
missing DRI had statistically similar risk of graft failure compared to those with complete 
DRI (HR for missing DRI = 1.015, 95% CI 0.936-1.101; p=0.716). African Americans with 
missing DRI data had significantly worse graft failure than their counterparts with 
complete DRI data (HR for missing DRI = 1.114, 95% CI 1.033-1.200; p=0.005). Thus, 
by not including the patients with missing data, our analysis of disparity in graft survival 
between African Americans and Caucasians may actually be conservative. 
Discussion 
This study demonstrates that African American recipients receive significantly 
"riskier" organs as defined by the DRI than their Caucasian counterparts, and that this 
disparity cannot completely be explained by socioeconomic, immunologic, or other 
medical factors. Furthermore, this disparity on organ donor quality has a significant 
impact on graft survival. The negative effects of the donor quality disparity are illustrated 
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by our analysis of graft survival, in which the percent of excess hazard explained by 
matching on DRI was 25%. The analysis of graft survival between African Americans 
and Caucasians indicates that the contribution of DRI to the observed higher risk of graft 
failure in African Americans is most prominent in the higher DRI strata. Gaining a clear 
understanding of the reasons underlying the lack of access to quality organs faced by 
African Americans thus becomes crucial if outcomes are to be improved. 
The propensity matched model of DRI demonstrates that multiple immunologic, 
medical, and socioeconomic factors account for most, but not ali, of the disparity in DRI. 
Two of the most important contributors to the disparity in organ quality appear to be 
increased use of organs from African American and hepatitis C positive donors in African 
American recipients. Although matching for HLA type and region did reduce the disparity 
in usage of African American donor kidneys, the odds of an African American vs. a 
Caucasian receiving a kidney from an African American donor remained 1.2 after 
matching. That such a difference remains after extensive matching suggests the 
influence of unmeasured factors which merit further study, such as the role of minor 
blood group antigens. Other potential explanations include that African Americans 
recipients and donors may live in closer proximity to each other, or perhaps that 
transplant surgeons preferentially allocate organs to recipients of the same race. 
The fact that African Americans remain more likely to receive a kidney from a 
hepatitis C positive donor than their Caucasian counterparts after matching for recipient 
hepatitis C status presents a similar quandary. Given that the patients were also 
matched on educational achievement, it may be assumed that there existed a similar 
level of sophistication on the part of recipients in both groups. Despite this, African 
Americans apparently were more likely to receive a kidney from a hepatitis C positive 
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donor than their Caucasian counterparts. This continued differential suggests an 
opportunity for a more complete informed consent process. 
The underlying causes for the disparity in kidney donor quality faced by African 
Americans are likely multifactorial. Adjustment for socioeconomic, immunologic, and 
clinical factors closes the gap somewhat, giving evidence to their significant role in the 
disparity. Even when taking these factors into consideration, African Americans still 
receive significantly more "risky" organs than their Caucasian counterparts. Given the 
known barriers to transplantation faced by African Americans30, 52, transplantation with a 
lower quality organ may be preferable to remaining on dialysis; however, such a decision 
requires thoughtful and thorough informed consent and patient education. Furthermore, 
the disparities in deceased donor organ quality faced by African American recipients 
underscores the importance of efforts to increase living donation among the African 
American community. Successful examples of such educational efforts can be seen in 
the work of Callender and Foster 34,53. 
If the disparity in post-transplant outcomes between African Americans and 
Caucasians is to be remedied, then we clearly need to improve our efforts to understand 
and address the donor quality gap. It is upon the transplant community to ensure that 
the distribution of higher risk organs to African Americans as illustrated above is not the 
result of a failure of transparency on our part. Patients place a tremendous amount of 
trust in their physicians because of our "expert" status. We must ensure that such trust is 
not misplaced by taking extraordinary efforts to ensure that patients are properly 
educated to make the best decisions for themselves. Organ donor quality and its effect 
on post-transplant outcomes should be a mandatory part the discussion held with the 
patient when determining whether to accept a particular organ offer. Failure to clearly 
outline the risks posed by donor factors would be to perpetuate the disparity in the 
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quality of organs accepted by and for African American patients. As a prescriptive 
measure, we echo Rao's call to include the DRI, or a similar measure of organ quality, in 
both the allocation and consent processes45 . In the end, the decision of whether or not to 
accept a particular organ must lie with the patient, and be based on full disclosure of all 
relevant information and informed consent. Only when we have fully disclosed and 
discussed issues of organ quality with the patient can we say that informed consent has 
truly taken place. That such an informed consent process can be effective is evidenced 
by the fact that African Americans and Caucasians accepted organs from extended 
criteria donors at similar rates in this study. Were potential recipients made as aware of 
the risks of high DRI kidneys as they are of the risks of ECD kidneys, then perhaps the 
gap in DRI between African Americans and Caucasians would be mitigated. 
In this study we have outlined several factors that contribute to this gap in what 
is, to our knowledge, the largest study to systematically address donor quality issues in 
African American recipients. The disparities underscored by our study, such as use of 
hepatitis positive and African American donors, certainly have more subtle effects on 
graft survival than more traditional measures of donor quality such as the expanded 
donor criteria, which were not significantly different in the matched cohort. When taken 
all together, however, these small differences combine to produce a significant effect. It 
is through acknowledging and paying appropriate attention to all the small details of 
patient care that optimal outcomes are achieved. Furthermore, it may be preferable in 
the future to preferentially allocate higher risk organs to patients with shorter life 
expectancy in order to mitigate the effects of shorter expected graft longevity. 
Despite this data, there remain other unmeasured factors yet to be determined 
that merit future study. It will require further vigilance on the part of the transplant 
community going forward to ensure that one of these factors is not the failure to disclose 
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important issues of donor quality. Limitations of this study are largely a product of its 
observational nature. We have included a number of potential confounders that can 
potentially explain observed differences in DRI in our model; however, there may be 
other factors which were not included and may contribute to residual confounding. The 
most important of these is the inability to control for specific immunosuppression 
protocols, which is the factor which likely has the greatest impact on graft survival, and 
may have differing effectiveness across racial groups. Other factors may include minor 
blood group antigens and willingness on the part of the patient(of either race) to accept 
suboptimal organs as an alternative to remaining on dialysis54 . We have also used 
multivariable modeling of graft survival in order to control for the effects of confounders. 
Though this approach has been widely used in the literature, there is the possibility that 
such models do not completely remove the effects of confounding variables. Another 
weakness of our Cox regression model is that the hazard associated with DRI and 
African American race appear to change with time, thus making our estimates less 
precise than a model where race and DRI were treated as time dependent. Though such 
analysis would add precision to a model intended to predict survival, that was not the 
goal of the current manuscript. The Cox regression analysis was of death censored graft 
failure, which tends to overestimate risk in the setting of competing risks. Were death 
instead treated as a competing risk, the observed difference in graft survival between 
African American and Caucasians may differ from the findings in the current manuscript. 
Another potential weakness is our use of the DRI as a surrogate for organ 
quality, as it differs from traditional markers such as the expanded donor criteria. One 
particular potential weakness of the DRI is that it does not completely isolate donor 
factors, in that HLA mismatch is a product of both the donor and the recipient. 
Nonetheless, we feel that DRI is the most appropriate proxy for donor quality for the 
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reasons outlined previously in this manuscript. Finally, there were a number of patients 
in the original dataset for whom complete information was not available to calculate the 
DRI, and inclusion of these patients may potentially lead to somewhat different 
outcomes. Although our sensitivity analysis indicates that the patients with missing 
values were similar to those with complete data, the possibility of bias introduced by 
exclusion of patients with missing data still remains. 
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Table 2.1: Overall Recipient Characteristics 
African 
Caucasian American p-
Variable (n=33,405) (n=22,577) value 
Male Gender 20582 (61.6%) 13577 (60.1 %) <0.001 
Hepatitis C Positive 1022 (3.1%) 2178 (9.8%) <0.001 
Cytomegalovirus Positive 17373 (54.2%) 16079 (74.4%) <0.001 
EnBloc Transplant 478i1.5%) 321 (1.4%) 0.726 
Double Kidney Transplant 484(1.5%) 374 (1.7%J 0.050 
Age (mean, std) 48.3 (14.1) 52.4 (15.0) <0.001 
Peak Panel Reactive Antibody 
(median, lOR) 0(7) 0(14) <0.001 
A Locus Mismatch (median, IO~ 1 (1) 2 (1) <0.001 
B Locus Mismatch (median, IQR) 1 (1) 2 (1) <0.001 
DR Locus Mismatch (median, IQR) 1 (2) 1 (1) <0.001 
Total HLA Mismatch (median, lOR) 4 (3) 5 (1) <0.001 
Height (cm, mean, std) 170.2 (14.5) 171.1 (13.6) <0.001 
Days on the waitlist (median, lOR) 478 (702) 756 (973) <0.001 
Table 2.1: Comparison of recipient characteristics between African Americans and 
Caucasians. Categorical variables are presented as count(percentage). Abbreviations: 
std(standard deviation), iqr(interquartile range), HLA(human leukocyte antigen). 
Components of the DRI are highlighted in bold. 
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Variable (n=33,405) (n=22,577) value 
Donor Risk Index 1.17iO.43) 1.2710.451 <0.001 
Age (years, mean, std) 38.1 (17.2) 38.3 (16.81 0.186 
Terminal Cr (mg/dl, mean, 
std) 1.0810.851 1.14 (0.97) <0.001 
Weight (kg, mean, std) 77.4 (23.6) 77.7 (23.71 0.175 
Height (em, mean, std) 169.3117.71 169.2117.71 0.450 
Cold Ischemic Time (hours, 
mean, std) 18.4 (8.9) 18.919.51 <0.001 
Male Gender 19848 (59.4%1 13575160.1 %1 0.092 
African American Race 289618.67%1 4600120.37%1 <0.001 
History of Hypertension 8077 (24.18%) 5963 (26.41 %) <0.001 
History of Diabetes 1884 (5.64%) 1405 (6.22%) 0.004 
Death From Stroke 12865 (38.51 %) 8952 (39.21 o/~ 0.097 
Donation after Cardiac Death 2631 (7.88%) 1954 18.65°/~ 0.001 
Hepatitis C Positive 402 (1.20o/~ 1226 15.43o/~ <0.001 
Table 2.2: Comparison of donor characteristics by recIpient race. Categorical 
variablesare presented as count(percentage). Components of the Donor Risk Index are 
highlighted in bold. Abbreviations: std(standard deviation). 
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Table 2.3: Differences in Donor Risk Index Components in a Propensity Matched 
Cohort of African American and Caucasian Recipients 
Caucasian African P-
(n=2,446) American value 
(n=2,446) 
Donor Age (mean, std) 39.45(16.71 ) 39.67(16.76) 0.64 
Donor Weight(kg, mean, std) 79.00(24.42) 79.17(24.41 ) 0.80 
Donor Height (cm, mean, std) 169.4(17.7) 169.1(18.0) 0.61 
Cold Ischemic Time (hours, mean, 19.12(10.99) 18.75(9.56) 0.21 
std) 
B Locus Mismatch (median, iqr) 2 (1) 2 (1) 0.006 
DR Locus Mismatch (median,iqr) 1 (1) 1 (1) 0.03 
Donor Terminal Creatinine 1.16(0.83) 1.14(0.70) 0.45 
(mg/dl, mean, std) 
African American Donor 328(13.41 %) 385(15.74%) 0.02 
Diabetic Donor (n, %) 164(6.70%) 196(8.01%) 0.08 
Hypertensive Donor (n, %) 704(28.78%) 706(28.86%) 0.95 
CVA as cause of death (n, %) 984(40.23%) 974(39.82%) 0.77 
Hepatitis C Positive Donor (n, %) 48(1.96%) 97(3.97%) <0.001 
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DeD Donor (n, %) 245(10.02%) 273(11.16%) 
Double Kidney Transplant (n, %) 33(1.35%) 50(2.04%) 
En Bloc Transplant (n, %) 33(1.35%) 35(1.43%) 
Table 2.3 (cont). Abbreviations: DeD (donation after cardiac death), eVA 





Parameter P- Lower Upper Parameter Estimate value HR 95% 95% CI CI 
DRI 0.87 <0.001 2.38 2.23 2.54 
African American Race 0.26 <0.001 1.30 1.21 1.40 
AGE (years) -0.02 <0.001 0.98 0.98 0.99 
Weight (kg) 0.01 <0.001 1.01 1.01 1.01 
Etiology of Renal Failure 
(Reference: Hypertensive 
Nephrosclerosis) 
OTHER 0.14 0.04 1.15 1.01 1.32 
CRESCENTIC 
-0.96 0.05 0.38 0.14 1.02 GLOMERULONEPHRITIS 
MEMBRANOUS 0.08 0.51 1.09 0.85 1.40 GLOMERULONEPHRITIS 
MESANGIO-CAPILLARY 1 
-0.01 0.98 0.99 0.41 2.38 GLOMERULONEPHRITIS 
MESANGIO-CAPILLARY 2 1.19 0.24 3.28 0.46 23.33 GLOMERULONEPHRITIS 
IGA NEPHROPA THY -0.15 0.20 0.87 0.69 1.08 
ANTI-GBM 0.36 0.47 1.44 0.54 3.84 
FSGS 0.04 0.56 1.04 0.92 1.18 
REFLUX NEPHROPA THY -0.20 0.26 0.82 0.58 1.16 
POL YC YS TIC KIDNEYS -0.34 <0.001 0.71 0.62 0.82 
NEPHRITIS 0.19 0.23 1.21 0.89 1.65 
NEPHROPHTHISIS 0.80 0.17 2.22 0.71 6.91 
DIABETES - TYPE I INSULIN 0.18 0.81 1.19 0.29 4.90 DEPENDENT IJUVENILE ONSET 
DIABETES - TYPE /I NON- -0.40 0.49 0.67 0.22 2.08 
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INSULIN DEPENDENTIADUL T 
ONSET 
OXALA TE NEPHROPA THY 1.42 <0.001 4.13 2.06 8.31 
CYSTINOSIS -0.78 0.43 0.46 0.06 3.25 
FABRY'S DISEASE -0.94 0.35 0.39 0.06 2.76 
AMYLOIDOSIS -0.27 0.58 0.76 0.28 2.03 
SYSTEMIC LUPUS 0.24 0.01 1.27 1.07 1.50 ERYTHEMA TOSUS 
PROGRESSIVE SYSTEMIC 
-0.34 0.73 0.71 0.10 5.05 SCLEROSIS 
RENAL CELL CARCINOMA -0.42 0.18 0.65 0.35 1.22 
MYELOMA -0.26 0.79 0.77 0.11 5.47 
HEMOL YTIC UREMIC 0.31 0.30 1.37 0.75 2.48 SYNDROME 
HYPOPLASIAIDYSPLASIAIDYSG 
-0.21 0.61 0.81 0.36 1.81 ENSISIAGENESIS 
CORTICAL NECROSIS 0.44 0.66 1.56 0.22 11.08 
ACUTE TUBULAR NECROSIS 0.49 0.23 1.64 0.73 3.66 
MEDULLARY CYSTIC DISEASE 0.59 0.12 1.81 0.86 3.81 
SICKLE CELL ANEMIA -0.03 0.94 0.97 0.46 2.05 
ACQUIRED OBSTRUCTIVE 0.32 0.21 1.37 0.84 2.25 NEPHROPA THY 
ALPORT'S SYNDROME -0.70 0.01 0.50 0.29 0.86 
FAMILIAL NEPHROPA THY -0.40 0.49 0.67 0.22 2.08 
GOODPASTURE'S SYNDROME -0.15 0.66 0.86 0.45 1.67 
MALIGNANT HYPERTENSION 0.03 0.76 1.03 0.85 1.24 
HENOCH-SCHOENLEIN 0.15 0.84 1.16 0.29 4.64 PURPURA 
PRUNE BELL Y SYNDROME -0.58 0.56 0.56 0.08 3.98 
DIABETES - TYPE I NON-
INSULIN DEPENDENT 0.99 0.32 2.70 0.38 19.21 
IJUVENILE ONSET 
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DIABETES - TYPE II INSULIN 0.10 0.86 1.11 0.36 3.44 DEPENDENT IADUL T ONSET 
CHRONIC 
GLOMERULONEPHRITIS -0.20 0.03 0.82 0.68 0.98 
UNSPECIFIED 
MEMBRANOUS NEPHROPATHY 0.24 0.33 1.27 0.79 2.05 
CHRONIC 
GLOMERULOSCLEROSIS -0.44 0.13 0.65 0.37 1.14 
UNSPECIFIED 
ANALGESIC NEPHROPA THY 0.45 0.07 1.57 0.97 2.53 
RADIA TlON NEPHRITIS 0.56 0.43 1.75 0.44 7.01 
ANTIBIOTIC-INDUCED 1.07 0.06 2.91 0.94 9.05 NEPHRITIS 
CANCER CHEMOTHERAPY 0.03 0.96 1.03 0.33 3.20 INDUCED NEPHRITIS 
CALCINEURIN INHIBITOR 
-0.11 0.55 0.90 0.63 1.28 NEPHROTOXICITY 
HEROIN NEPHROTOXICITY 0.16 0.75 1.17 0.44 3.14 
RENAL ARTERY THROMBOSIS -0.83 0.41 0.44 0.06 3.11 
CHRONIC NEPHROSCLEROSIS-
-0.16 0.57 0.86 0.50 1.48 UNSPECIFIED 
CONGENITAL OBSTRUCTIVE 0.14 0.45 1.15 0.80 1.66 UROPATHY 
SCLERODERMA 0.54 0.15 1.72 0.82 3.63 
WEGENERS GRANULOMA TOSIS -0.84 0.01 0.43 0.23 0.84 
POLYARTERITIS -0.69 0.49 0.50 0.07 3.58 
SARCOIDOSIS -0.26 0.61 0.77 0.29 2.06 
LYMPHOMA 1.60 0.11 4.97 0.70 35.38 
NEPHROLITHIASIS 0.20 0.45 1.23 0.72 2.08 
DRUG RELA TED INTERSTITIAL 
-0.10 0.69 0.90 0.54 1.50 NEPHRITIS 
CHOLESTEROL EMBOLIZA TlON -0.51 0.61 0.60 0.09 4.29 
RAPID PROGRESSIVE 0.54 0.13 1.71 0.85 3.44 GLOMERULONEPHRITIS 
DIABETES MELLITUS - TYPE I -0.04 0.56 0.96 0.83 1.11 
DIABETES MELLITUS - TYPE II -0.02 0.69 0.98 0.90 1.08 
DIABETES MELLITUS - TYPE -0.31 0.15 0.73 0.48 1.12 
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OTHER / UNKNOWN 
Employment Status (reference: 
Employed) 
Unemployed 0.15 0.00 1.16 1.07 1.26 
Unknown 0.08 0.19 1.08 0.96 1.21 
UNOS Region (reference: Region 
11) 
Region 1 0.08 0.44 1.08 0.89 1.31 
Region 2 0.09 0.12 1.09 0.98 1.22 
Region 3 -0.19 0.00 0.83 0.74 0.93 
Region 4 0.06 0.39 1.06 0.93 1.22 
Region 5 -0.11 0.14 0.89 0.77 1.04 
Region 6 -0.10 0.38 0.91 0.73 1.13 
Region 7 -0.07 0.28 0.93 0.81 1.06 
Region 8 -0.04 0.59 0.96 0.82 1.12 
Region 9 0.05 0.46 1.05 0.92 1.21 
Region 10 -0.04 0.57 0.96 0.85 1.09 
Payment Source (reference: 
Private Insurance) 
Public insurance - Medicaid 0.17 0.03 1.19 1.02 1.39 
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Public insurance - Medicare FFS 0.13 0.00 1.14 1.05 1.24 (Fee for Service) 
Public insurance - Medicare & 0.15 0.00 1.16 1.06 1.28 Choice 
Public insurance - Department of 0.18 0.31 1.20 0.85 1.69 VA 
Public insurance - Other 0.03 0.85 1.03 0.73 1.47 government 
Free Care -1.20 0.23 0.30 0.04 2.15 
Public insurance - Medicare other 1.06 <0.001 2.88 1.74 4.79 detail not specified 
Hepatitis C Status (reference = 
unknown) 
Negative -0.10 0.21 0.90 0.77 1.06 
Not Determined -0.03 0.73 0.97 0.80 1.17 
Positive 0.02 0.81 1.02 0.85 1.24 
Table 2.4: Multlvanable Cox regression model of death censored graft failure Including 
recipient race, donor risk index, and other potentially relevant covariates using a forward 
selection model. Hazard ratios are presented relative to the reference class for 
categorical covariates and for each one unit increase for continuous covariates. 
Parameter estimates and corresponding 95% confidence intervals are given for factors 
that reached statistical significance and thus were included in the final model. Factors 
that did not reach significance and thus were not included in the model were as follows: 
recipient body mass index, recipient creatinine, days on the waiting list, peak panel 
reactive antibody, recipient ABO blood group, recipient HLA antigens (a locus, b locus, 
and dr locus), recipient diabetes status, recipient cytomegalovirus status, recipient 
gender, and recipient educational achievement. 
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Figure 2.2: Distribution of Propensity Score in Caucasian and African American 
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A PROPENSITY MATCHED ANALYSIS OF LAPAROSCOPIC VERSUS OPEN 
RESECTION OF HEPATIC COLORECTAL METASTASES 
Since the first reports of limited laparoscopic liver resection in the first half of the 
1990s, the application of minimally invasive techniques to hepatic surgery has been 
relatively slow55 . Acceptance of the technique within specialized centers has been 
steadily gaining ground since Cherqui's initial report of 30 laparoscopic hepatectomies. A 
recent review by Nguyen demonstrated 2,804 cases reported in the world literature56,57. 
Experienced centers are now performing the majority of liver resections in a minimally 
invasive fashion, with several now reporting series of 300 patients or more58, 59. 
With respect to indication, laparoscopic resection for benign lesions gained 
acceptance relatively early on26, 60. Enthusiasm for laparoscopic resection of malignant 
lesions has been slower to develop, owing to concerns about the oncologic adequacy of 
laparoscopic hepatectomy61. In the realm of colorectal cancer, laparoscopic resection of 
the primary tumor has been demonstrated by randomized controlled trials to be 
oncologically equivalent to open surgery, with the benefit of shorter postoperative length 
of stay62. We have recently demonstrated the significant benefits of laparoscopic 
hepatic lobectomy in comparison to open hepatic lobectomy with benefits of reduction in 
adverse events, incision related adverse events, and reduction in hospital stay63. There 
have now been a handful of retrospective reports demonstrating the equivalence of 
laparoscopic and open hepatic resection for colorectal metastases as weIl64-66. This 
study was undertaken to evaluate the safety and efficacy of 
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laparoscopic resection of hepatic colorectal metastases as compared to a matched 
group of patients undergoing open resection. 
Patients and Methods 
With IRS approval, a retrospective review of all patients undergoing laparoscopic 
first resection of hepatic colorectal metastases by the division of surgical oncology at the 
University of Louisville from 1995 to 2010 was undertaken. These patients were 
compared to a cohort of patients undergoing open resection during the same period that 
were matched on a 1: 1 basis. Matching was by propensity scoring6 , with scores based 
on patient age, size and number of lesions, performance of major hepatectomy or 
synchronous colectomy, and Fong score6? 
Propensity scores were estimated by logistic regression, with the propensity 
toward laparoscopic treatment [e(x)] being specified as follows: 
e(x) _ -1 
log 1 _ e(x) - {J x 
Where 13-1 is the vector of regression coefficients and x is the vector of covariates as 
listed above. 
After estimation of propensity scores, matched cohorts were created using 
greedy nearest neighbor matching within a caliper of 0.1, as described in Chapter II. Two 
propensity matched groups were constructed. In the "inclusive" cohort, controls 
undergoing open resection were selected from the group of all patients undergoing open 
resection from 1995 through 2010. A "restricted" cohort was also created in which the 
controls undergoing open resection were selected from a group limited to those 
undergoing open resection from 2004 (when the first laparoscopic resection was 
performed) through 2010. The rationale for analyzing the inclusive and restricted cohorts 
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separately is to limit both era bias and selection bias. Use of controls from the earlier 
time period in the inclusive cohort has the limitation that there have been improvements 
in patient care and adjuvant therapy over the past two decades. Thus, utilization of 
controls undergoing open operation may introduce bias due to the improved adjuvant 
therapy in the laparoscopic cohort, which represents a more recent group of patients. On 
the other hand, using controls who underwent operation prior to the introduction of 
laparoscopy minimizes selection bias, in that even the "easy" cases underwent open 
resection prior to the introduction of laparoscopy. In the restricted cohort, the patients 
undergoing open and laparoscopic resection are contemporaneous, thus minimizing 
the effect of changes in adjuvant therapy. On the other hand, the restricted cohort is 
subject to greater selection bias as the more difficult cases preferentially receive an 
open operation. 
Balance of the baseline covariates was assessed using the paired t-test for 
continuous covariates and Mcnemar's test for categorical covariates. Further 
comparisons were made between the matched groups in terms of patient demographics, 
tumor characteristics, operative factors, short term outcomes, and overall (OS) and 
disease free (DFS) survival. Resection margins were defined as either micsrocopically 
positive (R1) or negative (RO). Baseline comorbidities were assessed using the Charlson 
Comorbidity Index68 . Continuous variables were summarized as mean(standard 
deviation) or median(interquartile range) and analyzed using the paired t-test or the 
Spearman signed rank test, where appropriate. Categorical variables were summarized 
as count(percentage) and compared using Mcnemar's test. Overall survival was 
calculated from the time of resection to death or last followup according to Kaplan-Meier, 
while disease free survival was the time from resection to recurrence, death, or last 
followup. Differences in survival curves were compared using the log rank test or Cox 
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proportional hazards regression. All statistical analyses were performed using SAS 
version 9.3 (SAS Institute, Cary, NC), and p-values less than 0.05 were considered 
significant. 
Results 
Analysis of the Inclusive Cohort 
There were 35 patients in the laparoscopic cohort and 35 patients in the open 
cohort. The groups were well matched on age, tumor size and number, body mass index 
(8MI), Fong score, and Charlson Comorbidity Index68(CCI) (Table 1.3). In terms of 
operative procedure performed, 19(54.3%) of patients in the laparoscopic cohort 
underwent major hepatectomy compared to 18(51.4%) in the open cohort 
(p=0.808).Synchronous colectomy was undertaken in 3(8.6%) patients in the 
laparoscopic cohort and 2(5.7%) patients in the open cohort (p=0.655). 
Patients in the laparoscopic group had Significantly less operative blood loss 
(202m I vs. 457ml; p=0.002) than those undergoing open resection. Transfusions were 
required in 4 (15.4%) patients undergoing laparoscopic resection compared to 8 (30.8%; 
p=0.206) in the open group. At least one postoperative complication was experienced 
significantly less often by patients in the laparoscopic versus open group (22.9% vs. 
48.6%; p=0.020). Among patients who did experience a complication, there was no 
significant difference in the median grade of worst complication between the 
laparoscopic and open groups (2.5 vs. 2.0; p=1.0). Length of stay was an average of 4.8 
days versus 7.6 days in the laparoscopic versus open groups (p=0.001). Ninety day 
mortality was 2.9% in both cohorts (p=1.0). 
In terms of oncologic outcome, RO resection was achieved in 97.1 % (n=34) of 
laparoscopically resected patients compared to 82.9% (n=29) of patients in the open 
43 
cohort (p=0.059). Overall survival at 1, 3, and 5 years in the laparoscopic and open 
cohorts was 96.9%, 62.6%, and 35.8% versus 100.0%, 66.1 %, and 40.8% (Figure 3.1; 
p=0.484). Disease free survival in the laparoscopic and open cohorts was 79.3%, 
36.96%, and 15.4% versus 90.7%, 43.6%, and 26.2% at 1, 3, and 5 years (Figure 3.2; 
p=0.117). There were no recurrences at laparoscopic port sites or at the laparotomy 
incision. 
Analysis of the Restricted Cohort 
There were 35 patients undergoing laparoscopic resection and 35 matched 
patients in the open cohort. The groups were well matched on age, tumor size and 
number, body mass index (8MI), Charlson Comorbidity Index68(CCI), and Fong score 
(Table 3.1). Major hepatectomy was performed in 54.3% (n=19) of patients undergoing 
laparoscopic resection compared to 42.9% (n=15; p=0.371) of patients undergoing open 
resection. A synchronous colectomy was performed in 8.6% (n=3) of the laparoscopic 
cohort and 8.6% (n=3; p=1.0) of the open cohort. 
Average blood loss was statistically similar in the laparoscopic and open groups 
(202ml vs. 327ml; p=0.213), as were rates of blood transfusion (15.4% vs. 34.6%; 
p=0.096). At least one postoperative complication was experienced in a significantly 
smaller percentage of the patients undergoing laparoscopic compared to open resection 
(22.9% vs. 48.6%; p=0.039). Of the patients who did experience a complication, the 
median grade of the worst complication was similar in the laparoscopic and open cohorts 
(2.5 vs. 2.5; p=1.0). Length of stay was significantly shorter in the laparoscopic vs. open 
cohort (4.8 days vs. 7.3 days; p=0.042). 
In terms of oncologic outcomes, patients undergoing laparoscopic resection were 
significantly more likely to have a margin negative resection than patients in the open 
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cohort (97.1% vs. 80.0%; p=0.014).Overall survival at 1, 3, and 5 years in the 
laparoscopic and open cohorts was 96.9%, 62.6%, and 35.8% vs. 91.4%, 63.0%, and 
26.3% (Figure 3.3; p=0.535). Disease free survival at 1, 3, and 5 years in the 
laparoscopic and open cohorts was 79.3%, 36.9%, and 15.4% vs. 79.3%, 45.0%, and 
15.0% (Figure 3.4; p=0.637), respectively. 
Discussion 
Results with open resection of hepatic colorectal metastases have been 
excellent, with several centers reporting 5 year survival in excess of 50%69.70. The group 
at Memorial Sloan Kettering have reported ten year cancer specific survival to be 23%67 
in a series of over 1,000 patients. Given these excellent results, the bar has been set 
relatively high for the application of laparoscopic techniques to this disease. Specific 
concerns about the oncologic adequacy of laparoscopy in general include port site 
metastases, the trophic effect of pneumoperitoneum on malignant cells, and inability to 
adequately inspect the peritoneal cavity, and lack of tactile sensation when inspecting 
the liver61 . 71-75. 
Experience has shown these fears to be largely unfounded; however. In 
Nguyen's review of the world literature on laparoscopic liver resection, there were no 
port site recurrences reported following laparoscopic resection of hepatic colorectal 
metasases76. In the current study, there were no port-site recurrences. Randomized 
trials of laparoscopic colon resection for cancer also failed to demonstrate increased 
rates of wound recurrence with laparoscopy77. As such, fears over port site recurrence 
appear to be unsupported by the available evidence. 
Rates of margin negative resection in this series were also similar or better in the 
laparoscopic versus open cohorts in this study, demonstrating that adequate delineation 
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of intrahepatic tumor anatomy can be obtained during laparoscopic resection. It is worth 
noting here the importance of facility with laparoscopic ultrasound as a key factor in 
obtaining such results. The ability to perform intraoperative ultrasound has been noted 
as one of the pre-requisite skill sets necessary before embarking on a program of 
laparoscopic liver resection26 . Finally, overall and disease free survival were equivalent 
in the laparoscopic and open cohorts of this study. These results demonstrate that 
laparoscopic resection for hepatic colorectal metastasis is oncologically equivalent to 
open surgery. 
In addition to oncologic equivalency, we have also demonstrated a number of 
benefits to laparoscopic hepatectomy. Patients undergoing a minimally invasive 
procedure experienced significantly less operative blood loss, and experienced 
postoperative complications at less than half the rate of their counterparts in the open 
cohort. Furthermore, length of stay was significantly shorter in the laparoscopic cohorts. 
Another potential benefit of laparoscopic liver resection is for patients who present with 
synchronous disease. Simultaneous resection of both the primary tumor and hepatic 
metastases allows for less overall hospitalization by avoiding a second operation78 , and 
eliminates any delay in hepatectomy while patients receive adjuvant chemotherapy. The 
ability to perform laparoscopic hepatectomy extends the benefits of minimally invasive 
surgery to this patient population. These results confirm our prior study evaluating 
laparoscopic hepatic lobectomy versus open hepatic lobectomy in which there were less 
adverse events63 . 
Given the demonstrated patient benefits of laparoscopy across the field of 
surgery, it is unlikely that a randomized controlled trial of laparoscopic versus open 
hepatic resection will ever be undertaken. Thus, comparisons will be limited to 
observational studies that are potentially confounded by selection bias. A strength of the 
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current study is the utilization of propensity score based matching, which simulates 
randomization in eliminating the confounding effects of variables used to create the 
model. In utilizing this design, the treatment effect of laparoscopy versus open resection 
in this study is more accurately estimated49 . There remains the potential, however, that 
residual confounding by unmeasured variables continues to exist. Another limitation of 
this study is its relatively small sample size, with only 35 patients undergoing 
laparoscopic resection. Despite these drawbacks, it appears that laparoscopic resection 
is an effective and beneficial alternative to open resection for appropriately selected 
patients with hepatic colorectal metastases. Further study will be needed as experience 
increases to confirm these findings. 
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Inclusive Cohort Restricted Cohort 
Open Lap P-value Open Lap P-value 
Age (years, 61.3 62.3 62.7 62.3 
mean, std) (9.6) (9.5) 0.629 (10.51 19.51 0.858 
CCI 
(median, 
IQR) 4 (1) 4111 0.526 5111 4111 0.128 
8MI (kg/mZ, 28.6 28.1 27.7 28.1 
mean, std) 16.0) 18.01 0.865 16.61 18.01 0.956 
Size of 
Largest 
Tumor (cm, 4.7 4.2 4.2 




IQR) 111) 1111 0.162 1111 1111 0.648 
CEAattime 
of Liver 
Resection 45.2 52.0 71.6 52.0 




Tumor (n, 21 20(57. 23 20 
%) (60.0%) 1%) 0.808 (65.7%) (57.1%) 0.467 
Fong Score 
(median, 
IQR) 1 (1) ~(2) 0.306 2 (1) 2J2) 0.860 
Table 3.1: Baseline patient and tumor characteristics in the matched laparosopic and open 
cohorts. The inclusive cohort includes patients from 1995 through 2010, while the restricted 
cohort includes patients from 2002 through 2010. Continuous variables are presented as 
mean(standard deviation) or median(interquartile range) where appropriate, and categorical 
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Figure 3.1: Overall Survival (in months) in the matched open and laparoscopic groups of 
the inclusive cohort. 
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Figure 3.3: Overall Survival (in months) in the matched open and laparoscopic groups of 
the restricted cohort. 
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Product-Limit Survival Estimates 
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Herein I have presented an overview of the utilization of propensity score 
matching to reduce confounding in observational studies in the field of surgery. Although 
the preeminent role of the randomized controlled trial for causal inference is 
acknowledged, the field of surgery is unique in the limitations placed on conducting such 
studies. On the one hand, the invasive nature of surgical procedures prevents proper 
blinding, in that it would be unethical to perform a sham operation on patients in order to 
have a control group. Another difficulty encountered is patient willingness to be 
randomized. This is especially problematic in the evaluation of minimally invasive 
procedures. 
Often, minimally invasive procedures are developed prior to the conduct of any 
formal study of their efficacy. The problem encountered is that after a number of centers 
have established expertise in a particular minimally invasive procedure, patients will 
seek out those surgeons specifically so that they can have the less invasive procedure. 
Such patients are unlikely to consent to randomization that would potentially have them 
undergo a more invasive operation. This is the case with laparoscopic liver resection26 , 
which is why we are limited to observational studies such as the one presented in 
Chapter III of 
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this work. In other cases, the exposure to be studied is not modifiable by the 
investigators, such as patient race in the analysis presented in Chapter II. 
Given the limitations on the performance of randomized controlled trials in the 
field of surgery, analysis based on the propensity score allows the investigator to create 
a "quasi-randomized" study from observational data, with subsequently reduced bias in 
estimation of the average treatment effect6, 9. Propensity score analysis is not a cure all 
for the problem of bias, however, and investigators and readers of such studies must 
keep some caveats in mind. 
The principle limitation of propensity score analysis is that of the strongly 
ignorable treatment assignment assumption6, which Austin has also named the 
requirement of "no unmeasured confounders"? A propensity matched cohort represents 
selection of patients on observable covariates. Thus, any propensity analysis is subject 
to bias introduced by potential confounders that were not measured. This is a particular 
problem with retrospective studies such as those presented in Chapters II and III above. 
For example, patients are now selected for laparoscopic or open liver resection based 
on the surgeon's experience and perceived difficulty of the procedure. These two factors 
are not distinctly quantifiable. Though the analysis in Chapter III was confined to a single 
center, differences in surgeon experience are not likely to affect treatment selection. 
Percieved difficulty of the operation, on the other hand, could not be measured directly 
and thus controlled for. In this case, we are forced to use surrogates for difficulty, such 
as tumor size and number, and requirement for a major hepatectomy in the case of the 
analysis in Chapter III. It remains likely though, that these surrogates did not completely 
capture the perceived difficulty of the operation, thus leaving the potential for residual 
bias in the study. 
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Another requirement of the strong ignorability assumption is that there must be 
enough overlap in propensity scores between the treated and control groups. As noted 
in Chapter I, a simple nearest neighbor matching algorithm may lead to poor matches for 
treated subjects in the upper tail of the propensity score distribution. Imposition of an 
appropriate caliper on the maximum difference in propensity scores for a match to be 
valid has thus become a popular and important method of ensuring that the matched 
samples are limited to the region of common support7, 18, 20. 
Finally, a propensity score matching scheme is only as good as the balance 
attained between the treated and control groups on measured covariates. Thus, 
ensuring proper assessment of balance is critical. Although the most appropriate method 
for evaluating balance remains a controversial subject, it is critical for investigators to 
explicitly state the methodology used and results of such analysis in order for readers to 
properly evaluate the study. Currently, it appears that either the method of standardized 
difference suggested by Austin20 or the use of hypothesis tests for paired data2,24 are 
both acceptable. With the above mentioned caveats, propensity matching is a valuable 
tool for creating nearly unbiased estimates of the treatment effect in cases where proper 
randomized studies are either infeasible or impossible. 
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